Edesa Biotech, Inc. (EDSA) will be presenting phase 3 study results of its drug candidate Paridiprubart, as a treatment for acute respiratory distress syndrome, at the American Thoracic Society (ATS) 2026 International Conference in May of this year.
Acute Respiratory Distress Syndrome (ARDS) occurs when the lungs become severely inflamed, making it hard for oxygen to reach the blood. It can be triggered by severe infections like pneumonia, inhaling smoke or chemicals, sepsis (a body-wide infection), chest injuries, and other serious illnesses. ARDS accounts for 10% of intensive care unit admissions, representing more than 3 million patients globally each year.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.